Q-omics provides the consensus-scored USP37 profile across patient tissues and cancer cell-line models. USP37 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP37 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, USP37 RNA expression shows 21,161 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where USP37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP37 survival associations across molecular data types. USP37 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP37 RNA expression–survival associations across cancer types. High USP37 expression shows unfavorable associations in ACC, MESO and BLCA, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP37 RNA expression.
This table summarizes USP37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP37 shows lower tumor expression in KICH and THCA and higher tumor expression in BRCA, STAD, LUAD and LUSC. The KICH box plot shows higher USP37 RNA expression in normal versus tumor tissue (log2 FC = −1.142, t-test p < 0.001).
This table shows molecular features associated with USP37 in patient tissues and cancer cell lines. In patient samples, USP37 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
